Inhalation Research Services chosen for new research project worth 1.45 million SEK by US pharma company
(Stockholm 18 July 2022) A US company with an extensive pipeline in medical dermatology has chosen Inhalation Research Services (IRS), ISAB’s contract research organization, for a research project worth 1.45 million SEK (1.36 K Euro) into a new repurposed drug that is being reformulated for administration via the lungs. ISAB’s world-class expertise in inhalation, and its high-precision IPL (Isolated Perfused Lung) solution, were decisive in the client’s choice.The new US client has chosen ISAB’s ex vivo IPL (Isolated Perfused Lung) solution to test its new repurposed drug that is being